GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (OSTO:XSPRAY) » Definitions » EV-to-Revenue

XSpray Pharma AB (OSTO:XSPRAY) EV-to-Revenue : (As of May. 31, 2025)


View and export this data going back to 2017. Start your Free Trial

What is XSpray Pharma AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, XSpray Pharma AB's enterprise value is kr1,165.53 Mil. XSpray Pharma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.00 Mil. Therefore, XSpray Pharma AB's EV-to-Revenue for today is .

The historical rank and industry rank for XSpray Pharma AB's EV-to-Revenue or its related term are showing as below:

During the past 10 years, the highest EV-to-Revenue of XSpray Pharma AB was 18164.76. The lowest was 462.49. And the median was 3670.13.

OSTO:XSPRAY's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.42
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-31), XSpray Pharma AB's stock price is kr31.35. XSpray Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.00. Therefore, XSpray Pharma AB's PS Ratio for today is .


XSpray Pharma AB EV-to-Revenue Historical Data

The historical data trend for XSpray Pharma AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB EV-to-Revenue Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XSpray Pharma AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XSpray Pharma AB's EV-to-Revenue

For the Biotechnology subindustry, XSpray Pharma AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XSpray Pharma AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's EV-to-Revenue falls into.


;
;

XSpray Pharma AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

XSpray Pharma AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1165.525/0
=

XSpray Pharma AB's current Enterprise Value is kr1,165.53 Mil.
XSpray Pharma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XSpray Pharma AB  (OSTO:XSPRAY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

XSpray Pharma AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=31.35/0
=

XSpray Pharma AB's share price for today is kr31.35.
XSpray Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XSpray Pharma AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


XSpray Pharma AB Business Description

Traded in Other Exchanges
Address
Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines